Treatment with TLR-7, -8, and -9 antagonists in these mice was shown to reduce both psoriasis-related skin lesions, inhibit the dermal expression of NLRP3 and AIM2, and decrease the secretion of Th1 and Th17 cytokines in the skin and serum. This evidence concerns the gene NLRP3 and psoriasis.